INmune Bio Inc. Presents Preclinical Data At SITC 2023 Showing INB03 Is An Innate Immune Check Point Inhibitor That Downregulates SIRPα
Portfolio Pulse from Benzinga Newsdesk
INmune Bio, Inc. (NASDAQ:INMB) presented preclinical data at SITC 2023 showing that INB03, a dominant-negative inhibitor of soluble TNF, downregulates expression of SIRPα on macrophages to promote increased cancer cell death. The research examined animal models and human macrophages, showing that INB03 neutralizes sTNF, repolarizes tumor protecting M2 macrophages to M1 anti-tumor macrophages, enhances ADCP with trastuzumab, and reduces SIRPα expression. INB03 has completed an open label dose-escalation Phase I trial in patients with advanced cancer and was found to be safe and well tolerated.
October 30, 2023 | 1:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
INmune Bio's INB03 has shown promising preclinical results in promoting cancer cell death. The drug has completed a Phase I trial and is moving into Phase II, indicating progress in its development pipeline.
The news of INmune Bio's INB03 showing promising preclinical results and moving into Phase II trials is directly relevant to the company and its stock. This progress in the drug development pipeline could potentially lead to future revenue growth if the drug is successfully commercialized. Therefore, this news is likely to have a positive impact on INMB's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100